{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:39:56Z","timestamp":1794580796027,"version":"4.9.1"},"reference-count":84,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5,14]]},"DOI":"10.1093\/eurheartj\/ehw454","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T22:43:43Z","timestamp":1477608223000},"page":"1455-1462","source":"Crossref","is-referenced-by-count":44,"title":["Management of antithrombotic therapy after bleeding in patients with coronary artery disease and\/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis"],"prefix":"10.1093","volume":"38","author":[{"given":"Sigrun","family":"Halvorsen","sequence":"first","affiliation":[{"name":"1Department of Cardiology, Oslo University Hospital Ulleval and University of Oslo, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[{"name":"2Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"3Institute of Pharmacology, Catholic University School of Medicine, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Sibbing","sequence":"additional","affiliation":[{"name":"4Medizinische Klinik und Poliklinik I, Ludwig-Maximilians-Universit\u00e4t, Munich, Germany and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurrien","family":"ten Berg","sequence":"additional","affiliation":[{"name":"5Department of Cardiology, St Antonius Hospital, Nieuwegein, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Lerkevang","family":"Grove","sequence":"additional","affiliation":[{"name":"6Department of Cardiology, Aarhus University Hospital, and Institute of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Weiss","sequence":"additional","affiliation":[{"name":"73rd Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Montleartstrasse 37, Vienna, A-1160, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[{"name":"8Univ Paris 06 (UPMC), ACTION Study Group, INSERM UMR_S 1166, ICAN, Institut de Cardiologie, Piti\u00e9-Salp\u00eatri\u00e8re Hospital (AP-HP), Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicita","family":"Andreotti","sequence":"additional","affiliation":[{"name":"9Institute of Cardiology, Catholic University Medical School, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich C.","family":"Gulba","sequence":"additional","affiliation":[{"name":"10Clinic for Internal Medicine and Pneumology, Katholisches Klinikum Oberhausen GmbH, St. Marien Hospital, Oberhausen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[{"name":"11University of Birmingham Institute of Cardiovascular Sciences, City Hospital, United Kingdom; and Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Husted","sequence":"additional","affiliation":[{"name":"12Medical Department, Region Hospital West, Herning\/Holstebro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Vilahur","sequence":"additional","affiliation":[{"name":"13Cardiovascular Research Center, CSIC-ICCC, HSCSP-Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"14Department of Cardiology, Leiria Hospital Centre, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek W.A.","family":"Verheugt","sequence":"additional","affiliation":[{"name":"15Emeritus Professor of Cardiology, P.C. Hooftstraat 188, CH Amsterdam, 1071, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Lanas","sequence":"additional","affiliation":[{"name":"16Service of Digestive Diseases. University Hospital. University of Zaragoza. CIBERehd. IIS Arag\u00f3n. Zaragoza, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rustam","family":"Al-Shahi Salman","sequence":"additional","affiliation":[{"name":"17Centre for Clinical Brain Sciences, University of Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"18Universit\u00e9 Paris-Diderot, Sorbonne Paris Cit\u00e9, DHU FIRE, AP-HP and INSERM U-1148, all in Paris, France. NHLI, Imperial College, Royal Brompton Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[{"name":"73rd Department of Internal Medicine, Cardiology and Intensive Care Medicine, Wilhelminen Hospital, Montleartstrasse 37, Vienna, A-1160, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the ESC Working Group on Thrombosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,10,27]]},"reference":[{"key":"2026081001063897600_ehw454-B1","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMoa0909475","article-title":"Dose comparisons of clopidogrel and aspirin in acute coronary syndromes","volume":"363","author":"Mehta","year":"2010","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B2","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/eurheartj\/ehn358","article-title":"Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes","volume":"30","author":"Budaj","year":"2009","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B3","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1056\/NEJMoa062437","article-title":"Bivalirudin for patients with acute coronary syndromes","volume":"355","author":"Stone","year":"2006","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B4","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(14)60924-7","article-title":"Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial","volume":"384","author":"Shahzad","year":"2014","journal-title":"Lancet"},{"key":"2026081001063897600_ehw454-B5","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"2026081001063897600_ehw454-B7","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1093\/eurheartj\/ehs012","article-title":"The association of in-hospital major bleeding with short-, intermediate-, and long-term mortality among older patients with non-ST-segment elevation myocardial infarction","volume":"33","author":"Lopes","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B8","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B9","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.jcin.2011.02.011","article-title":"Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2, ACUITY, and HORIZONS-AMI trials","volume":"4","author":"Mehran","year":"2011","journal-title":"JACC Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B10","first-page":"182","article-title":"Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age","volume":"83","author":"Ndrepepa","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B11","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jcin.2014.01.162","article-title":"Prognostic value of access site and nonaccess site bleeding after percutaneous coronary intervention: a cohort study in ST-segment elevation myocardial infarction and comprehensive meta-analysis","volume":"7","author":"Kikkert","year":"2014","journal-title":"JACC Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4244\/EIJY14M09_11","article-title":"Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial","volume":"11","author":"Ducrocq","year":"2015","journal-title":"EuroIntervention"},{"key":"2026081001063897600_ehw454-B13","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/eurheartj\/ehu463","article-title":"Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial","volume":"36","author":"Held","year":"2015","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ahj.2010.01.016","article-title":"Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents","volume":"159","author":"Ben-Dor","year":"2010","journal-title":"Am Heart J"},{"key":"2026081001063897600_ehw454-B15","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2008.07.063","article-title":"Impact of \u201cnuisance\u201d bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation","volume":"102","author":"Roy","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026081001063897600_ehw454-B16","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1093\/eurheartj\/ehv304","article-title":"Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis","volume":"36","author":"Andreotti","year":"2015","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for Dabigatran Reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/hrt.2011.224519","article-title":"Non-cardiac surgery in patients with coronary stents: the RECO study","volume":"97","author":"Albaladejo","year":"2011","journal-title":"Heart"},{"key":"2026081001063897600_ehw454-B19","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/S0140-6736(13)61720-1","article-title":"Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study","volume":"382","author":"Mehran","year":"2013","journal-title":"Lancet"},{"key":"2026081001063897600_ehw454-B20","first-page":"183","article-title":"Influence of bleeding on haemorheology and haemostasis in surgery","volume":"46","author":"Stephan","year":"2010","journal-title":"Clin Hemorheol Micro"},{"key":"2026081001063897600_ehw454-B21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11239-010-0513-1","article-title":"Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy","volume":"31","author":"Campbell","year":"2011","journal-title":"J Thromb Thrombolysis"},{"key":"2026081001063897600_ehw454-B22","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/EJA.0b013e32835f4d5b","article-title":"Management of severe perioperative bleeding: guidelines from","volume":"30","author":"Kozek-Langenecker","year":"2013","journal-title":"The European Society of Anaesthesiology. Eur J Anaesthesiol"},{"key":"2026081001063897600_ehw454-B23","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1538-7836.2011.04432.x","article-title":"Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents","volume":"9","author":"Levi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"2026081001063897600_ehw454-B24","article-title":"Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis","author":"Niessner","year":"2015","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B25","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"2026081001063897600_ehw454-B27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Camm","year":"2012","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B28","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B29","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting","volume":"367","author":"Collet","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B30","first-page":"871.","article-title":"Bedside monitoring of antiplatelet therapy for coronary stenting","volume":"368","author":"De Caterina","year":"2013","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B31","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: task force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B33","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1161\/CIRCULATIONAHA.108.813667","article-title":"Safety of short-term discontinuation of antiplatelet therapy in patients with drug-eluting stents","volume":"119","author":"Eisenberg","year":"2009","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2008.12.055","article-title":"Predictors of coronary stent thrombosis: the dutch stent thrombosis registry","volume":"53","author":"van Werkum","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026081001063897600_ehw454-B35","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.amjcard.2006.02.039","article-title":"Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up","volume":"98","author":"Park","year":"2006","journal-title":"Am J Cardiol"},{"key":"2026081001063897600_ehw454-B36","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1001\/jama.293.17.2126","article-title":"Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents","volume":"293","author":"Iakovou","year":"2005","journal-title":"JAMA"},{"key":"2026081001063897600_ehw454-B37","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/gut.2007.142497","article-title":"Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures","volume":"57","author":"Veitch","year":"2008","journal-title":"Gut"},{"key":"2026081001063897600_ehw454-B38","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.108.799403","article-title":"Long-term clinical outcome after a first angiographically confirmed coronary stent thrombosis: an analysis of 431 cases","volume":"119","author":"van Werkum","year":"2009","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B39","first-page":"550","article-title":"Contemporary clinical characteristics, treatment, and outcomes of angiographically confirmed coronary stent thrombosis: results from a multicenter California registry","volume":"79","author":"Yeo","year":"2012","journal-title":"Catheter Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B40","first-page":"2510","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"key":"2026081001063897600_ehw454-B41","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1160\/TH14-12-1066","article-title":"Comparative efficacy and safety of anticoagulant strategies for acute coronary syndromes. Comprehensive network meta-analysis of 42 randomised trials involving 117,353 patients","volume":"114","author":"Navarese","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026081001063897600_ehw454-B42","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1056\/NEJMoa1503943","article-title":"Polymer-free drug-coated coronary stents in patients at high bleeding risk","volume":"373","author":"Urban","year":"2015","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B43","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.4244\/EIJY14M07_11","article-title":"Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry","volume":"10","author":"Capodanno","year":"2015","journal-title":"EuroIntervention"},{"key":"2026081001063897600_ehw454-B44","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/CIRCULATIONAHA.110.003210","article-title":"Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings","volume":"123","author":"Kolandaivelu","year":"2011","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jcin.2016.03.038","article-title":"Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 Trials","volume":"9","author":"Kang","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B46","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacc.2015.12.062","article-title":"Platelet inhibition with ticagrelor 60\u2009mg versus 90\u2009mg twice daily in the PEGASUS-TIMI 54 trial","volume":"67","author":"Storey","year":"2046","journal-title":"J Am Coll Cardiol"},{"key":"2026081001063897600_ehw454-B47","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B48","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCOUTCOMES.111.962332","article-title":"Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial","volume":"5","author":"Roe","year":"2012","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026081001063897600_ehw454-B49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jcin.2008.03.019","article-title":"Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease","volume":"1","author":"Chan","year":"2008","journal-title":"JACC Cardiovasc Interv"},{"key":"2026081001063897600_ehw454-B50","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1093\/eurheartj\/ehl334","article-title":"A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50,279 patients at risk for coronary artery disease","volume":"27","author":"Biondi-Zoccai","year":"2006","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B51","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2796.2005.01477.x","article-title":"Low-dose aspirin for secondary cardiovascular prevention - cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation - review and meta-analysis","volume":"257","author":"Burger","year":"2005","journal-title":"J Intern Med"},{"key":"2026081001063897600_ehw454-B52","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1401105","article-title":"Aspirin in patients undergoing noncardiac surgery","volume":"370","author":"Devereaux","year":"2014","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B53","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/S0195-668X(03)00485-8","article-title":"Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE)","volume":"24","author":"Moscucci","year":"2003","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-152-1-201001050-00179","article-title":"Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial","volume":"152","author":"Sung","year":"2010","journal-title":"Ann Intern Med"},{"key":"2026081001063897600_ehw454-B55","doi-asserted-by":"crossref","first-page":"a1","DOI":"10.1055\/s-0034-1393172","article-title":"Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline","volume":"47","author":"Gralnek","year":"2015","journal-title":"Endoscopy"},{"key":"2026081001063897600_ehw454-B56","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/eht042","article-title":"Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy","volume":"34","author":"Agewall","year":"2013","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B57","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1161\/CIRCULATIONAHA.113.005754","article-title":"Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)","volume":"129","author":"Sherwood","year":"2014","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B58","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1161\/STROKEAHA.110.611905","article-title":"Withdrawal of antithrombotic agents and its impact on ischemic stroke occurrence","volume":"42","author":"Broderick","year":"2011","journal-title":"Stroke"},{"key":"2026081001063897600_ehw454-B59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1160\/TH15-01-0063","article-title":"Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. A meta-analysis","volume":"114","author":"Chai-Adisaksopha","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026081001063897600_ehw454-B60","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.amjcard.2013.10.044","article-title":"Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation","volume":"113","author":"Qureshi","year":"2014","journal-title":"Am J Cardiol"},{"key":"2026081001063897600_ehw454-B61","first-page":"33","article-title":"Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the best practice for reinitiating anticoagulation therapy after intracranial bleeding (BRAIN) study","volume":"28","author":"Yung","year":"2012","journal-title":"Can J Cardiol"},{"key":"2026081001063897600_ehw454-B62","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1001\/archinternmed.2012.4261","article-title":"Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding","volume":"172","author":"Witt","year":"2012","journal-title":"Arch Intern Med"},{"key":"2026081001063897600_ehw454-B63","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/europace\/euv309","article-title":"Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","volume":"17","author":"Heidbuchel","year":"2015","journal-title":"Europace"},{"key":"2026081001063897600_ehw454-B64","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.dld.2015.01.159","article-title":"Impact of new oral anticoagulants on gastrointestinal bleeding in atrial fibrillation: a meta-analysis of interventional trials","volume":"47","author":"Loffredo","year":"2015","journal-title":"Dig Liver Dis"},{"key":"2026081001063897600_ehw454-B65","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1161\/CIRCULATIONAHA.112.114967","article-title":"Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study","volume":"126","author":"Lamberts","year":"2012","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B66","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"2026081001063897600_ehw454-B67","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.jacc.2013.05.029","article-title":"Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention","volume":"62","author":"Lamberts","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026081001063897600_ehw454-B68","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial","volume":"65","author":"Fiedler","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026081001063897600_ehw454-B69","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1093\/eurheartj\/ehu298","article-title":"Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and\/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS)","volume":"35","author":"Lip","year":"2014","journal-title":"Eur Heart J"},{"key":"2026081001063897600_ehw454-B70","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B71","doi-asserted-by":"crossref","first-page":"e001512.","DOI":"10.1161\/JAHA.114.001512","article-title":"Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes","volume":"4","author":"Mahaffey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2026081001063897600_ehw454-B72","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: the ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026081001063897600_ehw454-B73","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/icvts\/ivs545","article-title":"When should you restart anticoagulation in patients who suffer an intracranial bleed who also have a prosthetic valve?","volume":"16","author":"Chandra","year":"2013","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2026081001063897600_ehw454-B74","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1212\/WNL.0000000000000245","article-title":"Recurrence of ICH after resumption of anticoagulation with VK antagonists: CHIRONE study","volume":"82","author":"Poli","year":"2014","journal-title":"Neurology"},{"key":"2026081001063897600_ehw454-B75","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1212\/WNL.0000000000000256","article-title":"Restarting anticoagulation after intracranial hemorrhage: a risky decision with no recipe","volume":"82","author":"Rabinstein","year":"2014","journal-title":"Neurology"},{"key":"2026081001063897600_ehw454-B76","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","article-title":"Optimal timing of resumption of warfarin after intracranial hemorrhage","volume":"41","author":"Majeed","year":"2010","journal-title":"Stroke"},{"key":"2026081001063897600_ehw454-B77","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2013-306476","article-title":"Long-term prognosis after intracerebral haemorrhage: systematic review and meta-analysis","volume":"85","author":"Poon","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026081001063897600_ehw454-B78","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1001\/jama.2015.0846","article-title":"Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage","volume":"313","author":"Kuramatsu","year":"2015","journal-title":"JAMA"},{"key":"2026081001063897600_ehw454-B79","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1161\/CIRCULATIONAHA.115.015735","article-title":"Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study","volume":"132","author":"Nielsen","year":"2015","journal-title":"Circulation"},{"key":"2026081001063897600_ehw454-B80","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1378\/chest.14-2099","article-title":"Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study","volume":"147","author":"Bronnum Nielsen","year":"2015","journal-title":"Chest"},{"key":"2026081001063897600_ehw454-B81","first-page":"2032","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American","volume":"46","author":"Hemphill","year":"2015","journal-title":"Stroke Association. Stroke"},{"key":"2026081001063897600_ehw454-B82","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","author":"Eikelboom","year":"2013","journal-title":"N Engl J Med"},{"key":"2026081001063897600_ehw454-B83","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.recesp.2012.09.013","article-title":"Defining the role of left atrial appendage closure in atrial fibrillation","volume":"66","author":"Andreotti","year":"2013","journal-title":"Rev Esp Cardiol"},{"key":"2026081001063897600_ehw454-B84","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehw159","article-title":"The left atrial appendage: from embryology to prevention of thromboembolism","author":"Patti","year":"2016","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/19\/1455\/70585680\/eurheartj_38_19_1455.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/19\/1455\/70585680\/eurheartj_38_19_1455.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:06:56Z","timestamp":1786338416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/19\/1455\/2418189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,27]]},"references-count":84,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2016,10,27]]},"published-print":{"date-parts":[[2017,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehw454","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,5,14]]},"published":{"date-parts":[[2016,10,27]]}}}